Get started
Author

Anne Seifert

Observed names: Anne SEIFERT, Seifert, Anne
OpenAlex ID: A5111656352
SUMO-targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage
2012 · Yili Yin, Anne Seifert, et al. · Genes & Development · 241
PDF
DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine
2008 · Anne Seifert, Lindsey A. Allan, et al. · FEBS Journal · 138
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
2025 · Luciano J. Costa, Nizar J. Bahlis, et al. · New England Journal of Medicine · 130
PDF
Ternary Complex Factor-Serum Response Factor Complex-Regulated Gene Activity Is Required for Cellular Proliferation and Inhibition of Apoptotic Cell Death
2004 · Elaine R. Vickers, Aneta Kasza, et al. · Molecular and Cellular Biology · 107
Proteotoxic stress reprograms the chromatin landscape of SUMO modification
2015 · Anne Seifert, Pietà Schofield, et al. · Science Signaling · 97
Screen for multi-SUMO–binding proteins reveals a multi-SIM–binding mechanism for recruitment of the transcriptional regulator ZMYM2 to chromatin
2015 · Elisa Aguilar-Martinez, Xi Chen, et al. · Proceedings of the National Academy of Sciences · 59
p38α- and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress
2009 · Anne Seifert, Paul R. Clarke · Cellular Signalling · 51
Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
2025 · María-Victoria Mateos, Nizar Bahlis, et al. · Blood · 10
PDF
Plenary Abstracts Session & Oral Presentations
2025 · Banerjee, Rahul, van de Donk, Niels W C J, et al. · HemaSphere · 7
OA-49 Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis
2026 · Luciano J. Costa, Nizar J. Bahlis, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Teclistamab Plus Daratumumab (tec-dara) in Patients (pts) With Relapsed Refractory Multiple Myeloma (rrmm): Analysis of Majestec-3 Based on Cytogenetic and Functional Risk
2026 · Rahul BANERJEE, Niels WCJ VAN DE DONK, et al. · Hematology Transfusion and Cell Therapy
MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
2026 · Rahul Banerjee, Niels WCJ van de Donk, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
2026 · Rahul Banerjee, Niels Wcj van de Donk, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 13
Citation count: 841
H-index: 8
I10-index: 8
Year
Topic
Type